AI
KZIA

Atom Investors’s Kazia Therapeutics KZIA Stock Holding History

Atom Investors’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,984
Closed -$857K – 344
2020
Q4 		$857K Buy
+1,984
New +$791K 0.09% 202

Other funds holding KZIA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Atom Investors's KZIA Position: Q1 2021 in Review

Atom Investors sold out of Kazia Therapeutics (KZIA) in Q1 2021, closing a stake of 1,984 shares — an estimated $857K sold.

Atom Investors first reported a position in KZIA in Q4 2020 and held it in 1 quarter. The position peaked at $857K in Q4 2020. 12 funds tracked by Wall St. Rank hold KZIA as of Q1 2021.

  • Atom Investors reported no remaining Kazia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Atom Investors sold 1,984 Kazia Therapeutics shares in Q1 2021, an estimated $857K.
  • Atom Investors first reported a position in Kazia Therapeutics in Q4 2020 and held it in 1 quarter.
  • Atom Investors's Kazia Therapeutics position peaked at $857K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2021.

Based on Atom Investors's 13F filing for Q1 2021, filed 17 May 2021.